For patients who have a suboptimal peak inspiratory flow rate and cannot improve breathing with a hand-held inhaler, nebulized anticholinergic therapy for COPD might be an efficient maintenance therapy option. In clinical trials, nebulized glycopyrrolate and revefenacin were well tolerated and did not increase the rate of cardiac-related events.
This review focuses on the subgroup of patients with an asthma phenotype predisposed to poor control a with conventional treatment strategy; the rationale for a single-inhaler, triple-therapy combination for this population; and evidence supporting its approval for clinical use.
“We suggest that, whenever possible, all PAH patients be evaluated promptly at a center with expertise in the diagnosis of PAH, ideally before the initiation of therapy.”(Ungraded consensus-based statement7) “We suggest also that contributing causes of PH (eg, sleep apnea and systemic hypertension) in patients with PAH be treated aggressively.”(Ungraded consensus-based statement7) “We suggest collaborative…
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, has now drawn attention with the publication of results from several clinical trials. The main targets of eosinophilic inflammation — interleukin (IL)-5 and T-helper-2 cells — cause a constellation of symptoms including asthma, sinusitis, eosinophilia, and necrotizing vasculitis.1,2 For years, oral glucocorticoids were considered first-line…
